dysport süstelahuse pulber
ipsen pharma - botulismitoksiin - süstelahuse pulber - 300ühik 1tk
dysport süstelahuse pulber
ipsen pharma - botulismitoksiin - süstelahuse pulber - 500ühik 1tk; 500ühik 2tk
alluzience süstelahus
ipsen pharma - botulismitoksiin - süstelahus - 200ühik 1ml 0.625ml 2tk; 200ühik 1ml 0.625ml 12tk; 200ühik 1ml 0.625ml 1tk
azzalure süstelahuse pulber
ipsen pharma - botulismitoksiin - süstelahuse pulber - 125ühik 1tk
zeel comp. n tablett
biologische heilmittel heel gmbh - homöopaatilised preparaadid - tablett - 50tk
infragil pekana pillid
pekana naturheilmittel gmbh - homöopaatilised preparaadid - pillid - 10g 1tk
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - mitu müeloomit - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
tecvayli
janssen-cilag international n.v. - teclistamab - mitu müeloomit - antineoplastilised ained - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
pedmarqsi
fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - kõik muud ravitoimingud - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.
talvey
janssen-cilag international n.v. - talquetamab - mitu müeloomit - antineoplastilised ained - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.